What’s in Heat Biologics Inc (HTBX) After Achieving 1 Year Low?

July 17, 2017 - By Darrin Black

Investors sentiment decreased to 1.4 in 2016 Q4. Its down 1.27, from 2.67 in 2016Q3. It is negative, as 1 investors sold Heat Biologics Inc shares while 4 reduced holdings. 2 funds opened positions while 5 raised stakes. 962,174 shares or 104.60% more from 470,276 shares in 2016Q3 were reported.
Creative Planning has invested 0% in Heat Biologics Inc (NASDAQ:HTBX). Royal National Bank & Trust Of Canada holds 0% in Heat Biologics Inc (NASDAQ:HTBX) or 1,035 shares. Geode Capital Mngmt Limited Liability Co stated it has 0% of its portfolio in Heat Biologics Inc (NASDAQ:HTBX). Natl Bank Of America Corp De accumulated 0% or 2 shares. Manufacturers Life Insurance The has 0% invested in Heat Biologics Inc (NASDAQ:HTBX) for 177 shares. Vanguard Grp reported 254,354 shares stake. Blackrock Fund Advsrs owns 2,372 shares for 0% of their portfolio. Citadel Advisors Limited Liability has invested 0% of its portfolio in Heat Biologics Inc (NASDAQ:HTBX). Goldman Sachs Group Inc Incorporated accumulated 0% or 17,323 shares. Blackrock Advisors Ltd Liability Corp invested in 2,991 shares or 0% of the stock. Art Limited Co accumulated 40,300 shares. Kcg reported 129,938 shares. The California-based Wells Fargo Co Mn has invested 0% in Heat Biologics Inc (NASDAQ:HTBX). Oxford Asset Mgmt accumulated 320,951 shares. Franklin Street Nc holds 70,500 shares or 0.01% of its portfolio.

The stock of Heat Biologics Inc (NASDAQ:HTBX) hit a new 52-week low and has $0.49 target or 9.00 % below today’s $0.54 share price. The 6 months bearish chart indicates high risk for the $19.65M company. The 1-year low was reported on Jul, 17 by Barchart.com. If the $0.49 price target is reached, the company will be worth $1.77M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 187,485 shares traded. Heat Biologics Inc (NASDAQ:HTBX) has risen 35.57% since July 17, 2016 and is uptrending. It has outperformed by 18.87% the S&P500.

Heat Biologics Inc (NASDAQ:HTBX) Ratings Coverage

Among 4 analysts covering Heat Biologics (NASDAQ:HTBX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heat Biologics had 6 analyst reports since September 1, 2015 according to SRatingsIntel. Noble Financial initiated the shares of HTBX in report on Friday, January 8 with “Buy” rating. Noble Financial maintained the stock with “Buy” rating in Wednesday, June 7 report. H.C. Wainwright maintained it with “Buy” rating and $13 target in Thursday, September 3 report. The stock of Heat Biologics Inc (NASDAQ:HTBX) has “Speculative Buy” rating given on Thursday, February 4 by Cantor Fitzgerald. The stock of Heat Biologics Inc (NASDAQ:HTBX) has “Buy” rating given on Tuesday, September 1 by Cantor Fitzgerald. The rating was initiated by Roth Capital with “Buy” on Monday, June 20.

More notable recent Heat Biologics Inc (NASDAQ:HTBX) news were published by: Globenewswire.com which released: “Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial …” on February 17, 2017, also Seekingalpha.com with their article: “Heat Biologics gets delisting notice from Nasdaq related to low bid price …” published on March 16, 2017, Bizjournals.com published: “Heat Biologics offers further bladder cancer treatment outlook” on February 21, 2017. More interesting news about Heat Biologics Inc (NASDAQ:HTBX) were released by: Globenewswire.com and their article: “Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in …” published on March 21, 2017 as well as Globenewswire.com‘s news article titled: “Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results at the …” with publication date: November 30, 2016.

Heat Biologics, Inc. is a development-stage firm focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The company has market cap of $19.65 million. The Firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). It currently has negative earnings. Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.